Clinical Trial Update: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate with or without everolimus in localized, unresectable, or metastatic liver cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED